Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
Marta Seghieri, Alexander S. Christensen, Andreas Andersen, et al.
Frontiers in Endocrinology (2018) Vol. 9
Open Access | Times Cited: 79

Showing 51-75 of 79 citing articles:

The Diabetes Syndrome – A Collection of Conditions with Common, Interrelated Pathophysiologic Mechanisms
Amy W. Rachfal, Struan F.A. Grant, Stanley S. Schwartz
International Journal of General Medicine (2021) Vol. Volume 14, pp. 923-936
Open Access | Times Cited: 10
Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4
Khaoula Errafii‬, Neyla S. Al-Akl, Olfa Khalifa, et al.
Journal of Translational Medicine (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 10
Lipid regulation of the glucagon receptor family
Affiong I Oqua, Yusman Manchanda, Emma Rose McGlone, et al.
Journal of Endocrinology (2024) Vol. 261, Iss. 3
Open Access | Times Cited: 1
From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists
Bhavarth P. Dave, Mehul R. Chorawala, Ishika V Shah, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 1
Fatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery
Luke V. Selby, Aslam Ejaz, Stacy A. Brethauer, et al.
Expert Opinion on Investigational Drugs (2020) Vol. 29, Iss. 2, pp. 107-110
Open Access | Times Cited: 10
Human skin stem cell-derived hepatic cells as in vitro drug discovery model for insulin-driven de novo lipogenesis
Karolien Buyl, Martine Vrints, Ruani Fernando, et al.
European Journal of Pharmacology (2023) Vol. 957, pp. 175989-175989
Open Access | Times Cited: 3
Peri-transplant renal dysfunction in patients with non-alcoholic steatohepatitis undergoing liver transplantation
Rakhi Maiwall, Manasvi Gupta
Translational Gastroenterology and Hepatology (2020) Vol. 5, pp. 18-18
Open Access | Times Cited: 6
Targeted microRNA Profiling Reveals That Exendin-4 Modulates the Expression of Several microRNAs To Reduce Steatosis in HepG2 Cells
Olfa Khalifa, Khalid Ouararhni, Khaoula Errafii‬, et al.
(2023)
Open Access | Times Cited: 2
Targeted MicroRNA Profiling Reveals That Exendin-4 Modulates the Expression of Several MicroRNAs to Reduce Steatosis in HepG2 Cells
Olfa Khalifa, Khalid Ouararhni, Khaoula Errafii‬, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11606-11606
Open Access | Times Cited: 2
Hunger & satiety signals: another key mechanism involved in the NAFLD pathway
Iván López-Méndez, Andrea del Carmen Maldonado-Rojas, Misael Uribe, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 2
Incretin Hormones in the Control of Immunometabolism
Sigal Fishman, Isabel Zvibel, Chen Varol
Immunometabolism (2019) Vol. 1, Iss. 1
Open Access | Times Cited: 5
A double‐blind, placebo‐controlled, single‐ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM15136, a novel long‐acting glucagon analogue, in healthy subjects
Ki Young Huh, Jun Gi Hwang, Won‐Jung Shin, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 3, pp. 411-420
Closed Access | Times Cited: 4
Traitements pharmacologiques de la NASH
Lawrence Serfaty
La Presse Médicale (2019) Vol. 48, Iss. 12, pp. 1489-1495
Open Access | Times Cited: 3
Unraveling the mechanisms of hepatogenous diabetes and its therapeutic perspectives
Manisha Yadav, Smriti Verma, Purnima Tiwari, et al.
Life Sciences (2024) Vol. 353, pp. 122934-122934
Closed Access
Are GLP-1 Analogues a New Solution for the Treatment of NAFLD?
Maria Sudoł, Katarzyna Dąbek, Michał Ochwat, et al.
Quality in Sport (2024) Vol. 35, pp. 56304-56304
Open Access
Antiobesity therapeutics with complementary dual‐agonist activities at glucagon and glucagon‐like peptide 1 receptors
Bong Gyu Park, Gyeong Min Kim, Hye‐Jin Lee, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 1, pp. 50-60
Closed Access | Times Cited: 3
Dislipidemias, hígado graso y enfermedad cardiovascular
Isabel Carrillo‐Hidalgo, Salvador Fonseca-Coronado, Guillermo Ceballos, et al.
Cardiovascular and Metabolic Science (2022) Vol. 33, Iss. 3, pp. 134-139
Open Access | Times Cited: 2
Obesity and non-alcoholic fatty liver disease: therapeutic options
Victor Kaschenko, A.I. Mitsinskaya, Alexey Y. Sokolov, et al.
Siberian medical review (2020), Iss. 3, pp. 20-29
Open Access | Times Cited: 2
Serotonin receptor HTR4 as a counter actor of lipid-induced increases of serum glucagon-like peptide-1 levels
Andreas Breit, Thomas Gudermann
Pflügers Archiv - European Journal of Physiology (2020) Vol. 472, Iss. 10, pp. 1433-1434
Open Access | Times Cited: 1
GLP-1 analogues in the treatment of obesity and non-alcoholic fatty liver disease
Kacper Deska, Bartłomiej Bąk, Marcin Kosmalski, et al.
Postępy Higieny i Medycyny Doświadczalnej (2023) Vol. 77, Iss. 1, pp. 1-8
Open Access
Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
I Dewa Nyoman Wibawa, I Ketut Mariadi, Gde Somayana, et al.
World Journal of Diabetes (2023) Vol. 14, Iss. 5, pp. 549-559
Open Access
ASSESSING THE ACCURACY OF FIB-4 SCORES TO POINT SHEAR WAVE ELASTOGRAPHY IN MONITORING DIFFERENT STAGES OF FIBROSIS IN NON-ALCOHOLIC LIVER DISEASE
Shahla Mohammed Saeed Rasul
Journal of Sulaimani Medical College (2023) Vol. 13, Iss. 3, pp. 5-5
Open Access
Kardiovaskuläre Effekte von GLP-1-Rezeptoragonisten
Florian Kahles, Michael Lehrke
Diabetes aktuell (2020) Vol. 18, Iss. 03, pp. 108-113
Closed Access

А. В. Протопопов, М. М. Петрова, E Romanova, et al.
Siberian medical review (2020), Iss. 3
Open Access
Metabolic Syndrome and Liver Cancer
Ariel Jaffe, Mario Strazzabosco
Springer eBooks (2022), pp. 87-104
Closed Access

Scroll to top